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Abstract
Introduction: Ghrelin has been recently identified as a mediator of various beneficial effects in animal models of 
sepsis. At present, no data are available concerning specific properties of ghrelin in critically ill patients from large 
cohorts. In order to identify possible pathogenic functions of ghrelin in critically ill patients and human sepsis from a 
clinical point of view, we aimed at analyzing ghrelin serum concentrations in a large cohort of well characterized 
patients with critical illness.
Methods: A total of 170 critically ill patients (122 with sepsis, 48 without sepsis) were studied prospectively on 
admission to the Medical intensive care unit (ICU) and compared to 60 healthy controls. Careful assessment of clinical 
data, various laboratory parameters, metabolic and endocrine functions as well as investigational inflammatory 
cytokine profiles have been performed, and patients were followed for approximately three years.
Results: Ghrelin serum concentrations are elevated in critically ill patients as compared to healthy controls, but do not 
differ between sepsis and non-sepsis patients. The underlying etiologies of critical diseases are not associated with 
ghrelin serum levels. Neither pre-existing diabetes mellitus nor body mass index is correlated to serum ghrelin 
concentrations. Ghrelin is not correlated to markers of inflammation or hepatic function in critically ill patients. In the 
subgroup of non-sepsis patients, ghrelin correlates inversely with renal function and markers of carbohydrate 
metabolism. High ghrelin levels are an indicator for a favourable prognosis concerning mortality at the ICU in sepsis 
patients. Furthermore, ghrelin is significantly associated with the necessity of ventilation in critically ill patients.
Conclusions: Ghrelin serum concentrations are elevated in all circumstances of critical disease, including sepsis and 
non-sepsis patients. High ghrelin levels are a positive predictor of ICU-survival in sepsis patients, matching previous 
results from animal models. Future experimental and clinical studies are needed to evaluate ghrelin as a novel 
prognostic tool in ICU patients and its potential therapeutic use in sepsis.
Introduction
Human ghrelin, a 28-amino acid peptide, is predomi-
nantly synthesized by the stomach and is the only identi-
fied endogenous ligand for the growth hormone
secretagogue receptor 1a (GHS-R1a) [1]. GHS-R1a is
expressed in various tissues in different concentrations
and has been found in pituitary, hypothalamus, heart,
blood vessels, lung, pancreas, intestine, kidney, adipose
tissue, B- and T-cells and neutrophils [2-4]. This wide dis-
tribution of GHS-R1a suggests multiple roles of ghrelin
with regard to cerebral, renal and pulmonary function,
hemodynamics, gut barrier and immune system. Never-
theless, about two third of the circulating ghrelin is
derived from the stomach and nearly all of the remaining
one third from the small intestine [5,6]. Rat ghrelin is very
similar to human ghrelin and differs only by two amino
acids [7]. Therefore animal models have been widely used
to investigate potential functions of ghrelin. Ghrelin stim-
ulates growth hormone secretion in rats and humans,
regulates food intake and energy homeostasis and has
vasodilatatory effects as a physiological antagonist of
endothelin-1 [8-10]. Moreover, protective effects of ghre-
lin in animal sepsis models have been reported. Specifi-
cally, ghrelin was found to mediate improvement of tissue
perfusion in severe sepsis [11], down-regulation of proin-
flammatory cytokines in sepsis through activation of the
vagus nerve [12], stabilization of gut barrier function in
sepsis [13], attenuation of sepsis-induced acute lung
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injury [14] and protection against endotoxemia-induced
acute kidney failure [15]. On the basis of these findings
GHS-R1a has been regarded as a possible drug target in
critical care medicine with ghrelin or a ghrelin mimetic as
a new therapeutic option [16].
Nevertheless, the findings on the responses of ghrelin
to endotoxin in animal models and in healthy humans are
partially contradictory and inconsistent. Beyond that,
there are no data concerning the mechanisms of regula-
tion in critically ill patients from large cohorts. Before
testing the possible therapeutic effects of ghrelin in
humans, clinical studies on profiles of endogenous ghre-
lin regulation in the critically ill have been demanded
[17]. Up to now, there has been only a small pilot study
with 16 ICU patients, reporting low initial, but, during
ICU treatment, increasing ghrelin serum concentrations
[18]. The present study was conducted with a large
cohort of well characterized critically ill patients to pro-
vide information on ghrelin serum concentrations in dif-
ferent circumstances of critical disease, to identify
possible pathogenic functions of ghrelin by correlations
with a wide number of markers of inflammation, organ
dysfunction and metabolism and to examine potential
protective effects of ghrelin in critically ill patients and
human sepsis from a clinical point of view.
Materials and methods
Study design and patient characteristics
The present study was approved by the local ethics com-
mittee. Before inclusion, written informed consent was
obtained from the patient, his or her spouse or the
appointed legal guardian. We studied 170 patients (111
male, 59 female with a median age of 62 years; range 18 to
86 years) (Table 1) [19]. Patients were included consecu-
tively upon admission to the Medical ICU of the RWTH
U n i v e r s i t y  H o s p i t a l  A a c h e n  d u e  t o  c r i t i c a l  i l l n e s s .
Patients were excluded from this study, if they were
expected to have a short-term (<72 h) intensive care
treatment, for example, due to post-interventional obser-
vation or acute intoxication. All patient data, clinical
information and blood samples were collected prospec-
tively.
Blood samples of 60 healthy non-diabetic blood donors
(33 male, 27 female, with a median age of 46 years; range
31 to 58 years) with normal values for blood counts, C-
reactive protein and liver enzymes have been examined as
a control group.
Characteristics of sepsis and non-sepsis patients
A total of 122 of the 170 critically ill patients (72%)
enrolled in this study, fulfilled the criteria of bacterial
sepsis, according to the American College of Chest Physi-
cians and the Society of Critical Care Medicine Consen-
sus Conference Committee for severe sepsis and septic
shock [20]. In the majority of sepsis patients the identified
origin of infection was pneumonia (Table 2). Non-sepsis
patients were admitted to the ICU due to cardiopulmo-
nary disorders (myocardial infarction, pulmonary embo-
lism, and cardiac pulmonary edema), decompensated
liver cirrhosis or other critical conditions and did not dif-
fer in age or sex from sepsis patients. As expected, signifi-
cantly higher levels of laboratory indicators of
inflammation (that is, C-reactive protein, procalcitonin,
white blood cell count) were found in sepsis patients than
i n  n o n - s e p s i s  p a t i e n t s  ( T a b l e  1 ,  a n d  d a t a  n o t  s h o w n ) .
Both groups did not differ in acute physiology and
chronic health evaluation (APACHE II) score, vasopres-
sor demand, or laboratory parameters indicating liver or
renal dysfunction (data not shown). ICU-mortality of all
critical care patients was 32%, and 52% of the total initial
cohort died during the overall follow-up of 900 days
(Table 1).
Comparative variables
The patients in the sepsis and non-sepsis groups were
compared by age, sex, body mass index (BMI), pre-exist-
ing diabetes mellitus and severity of disease using the
APACHE II score upon admittance to the ICU. Careful
recording of intensive care treatment, such as volume
therapy, vasopressor infusions, demand of ventilation and
ventilation hours, antibiotic and antimycotic therapy,
renal replacement therapy and nutrition, has been per-
formed. Additionally, a large number of laboratory
parameters that were routinely assessed during intensive
care treatment have been analyzed.
Quantification of ghrelin, IGF-1 and growth hormone 
serum concentrations
Peripheral venous blood samples were obtained at admis-
sion before therapeutic intervention, immediately placed
on ice, centrifuged and stored at 80°C. All patients had
been fasting for at least three hours before admission to
the ICU. All measurements were performed in a blinded
fashion. Ghrelin serum concentrations were measured
using an enzyme-linked immunosorbent assay (ELISA)
according to manufacturer's instructions (Millipore,
Schwalbach, Germany). Furthermore, growth hormone
(Immulite 2000 hGH, Siemens, Erlangen, Germany) and
IGF-1 (Immulite 2500 IGF-1, Siemens, Erlangen, Ger-
many) were measured by chemiluminescent immuno-
metric assay in the routine clinical laboratory.
Statistical analysis
Due to the skewed distribution of most of the parameters
in critically ill patients, data are given as median and
range. Differences between two groups were assessed by
Mann-Whitney-U-test and multiple comparisons
between more than two groups have been conducted by
Kruskal-Wallis-ANOVA and Mann-Whitney-U-test forKoch et al. Critical Care 2010, 14:R94
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post hoc analysis. Box plot graphics were employed to
illustrate comparisons between subgroups. They display a
statistical summary of the median, quartiles, range and
extreme values. The whiskers extend from the minimum
to the maximum value excluding outside and far out val-
ues which are displayed as separate points. An outside
value (indicated by an open circle) is defined as a value
that is smaller than the lower quartile minus 1.5-times
interquartile range, or larger than the upper quartile plus
1.5-times the interquartile range. A far out value is
defined as a value that is smaller than the lower quartile
minus three times the interquartile range, or larger than
the upper quartile plus three times the interquartile
range. All values, including outliers, have been included
for statistical analyses [19]. Correlations between vari-
ables have been analysed using the Spearman correlation
tests, where values of P <0.05 were considered statistically
significant. The prognostic value of the variables was
tested by univariate and multivariate analysis in the Cox
regression model. Kaplan Meier curves were plotted to
display the impact on survival. All statistical analyses
were performed with SPSS version 12.0 (SPSS, Chicago,
IL, USA).
Results
Ghrelin serum concentrations are elevated in critically ill 
patients as compared to healthy controls and are not 
different between sepsis or non-sepsis patients
In rat models of polymicrobial sepsis induced by cecal
ligation and puncture (CLP) as well as in a small pilot
Table 1: Baseline patient characteristics and ghrelin serum concentrations
Parameter All patients Sepsis non-Sepsis
Number 170 122 48
Sex (male/female) n 111/59 81/41 30/18
Age median (range) (years) 63
(18 to 86)
64
(20 to 86)
60
(18 to 79)
APACHE-II score median (range) 14
(0 to 31)
14
(0 to 31)
15
(0 to 31)
SAPS2 score median (range) 44
(0 to 80)
45
(0 to 79)
41
(13 to 80)
ICU days median (range) 8.5
(1 to 137)
10
(1 to 137)
6
(1 to 45)
Hospital days median (range) 27
(2 to 151)
30
(2 to 151)
14
(2 to 85)
Death during ICU n(%) 54 (32%) 42 (34%) 12 (25%)
Death during follow-up n(%) 88 (52%) 64 (53%) 24 (50%)
30-day mortality [%] 32% 32% 31%
60-day mortality [%] 39% 40% 35%
90-day mortality [%] 42% 44% 35%
180-day mortality [%] 45% 48% 38%
1-year mortality [%] 49% 51% 44%
Mechanical ventilation n(%) 113 (67%) 82 (67%) 31 (65%)
Ventilation time median (range) [h] 66
(1 to 2,966)
127.5
(1 to 2,966)
31
(1 to 755)
pre-existing diabetes n(%) 56 (33%) 39 (32%) 17 (35%)
BMI median (range) (m2/kg) 25.8
(14.0 to 59.5)
26.0
(14.0 to 59.5)
25.1
(17.5 to 53.3)
Serum IGF-1 median (range) (μg/L) 54
(25 to 295)
54
(25 to 295)
49
(25 to 165)
Serum growth hormone median (range) (μg/L) 1.5
(0.1 to 128.0)
1.3
(0.1 to 128.0)
2.0
(0.1 to 22.3)
Serum ghrelin median (range) (pmol/L) 18.4
(5.0 to 129.5)
18.4
(5 to 113.8)
18.4
(5 to 129.5)
APACHE: acute physiology and chronic health evaluation; BMI: body mass index; IGF-1, insulin-like growth factor-1; SAPS: simplified acute 
physiology scoreKoch et al. Critical Care 2010, 14:R94
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study with 16 critically ill surgical and medical patients,
decreased circulating levels of ghrelin have been reported
[18,21]. On the other hand, a later study proved signifi-
cantly increased ghrelin concentrations in response to
endotoxin administration in dogs [22]. To examine the
significance of ghrelin in humans in a genuine intensive
care environment we analyzed blood samples of critically
ill patients at admission to a Medical ICU . As demon-
strated in Figure 1a critical care patients had significantly
higher serum ghrelin levels than healthy volunteers
(median 9.6 pmol/L in controls vs. 18.4 pmol/L in
patients,  P  <0.001). However, there was considerable
overlap between controls and patients (Figure 1a). Ghre-
lin did not correlate with age or sex in either controls or
patients (data not shown). The subgroup analysis of sep-
tic and non-septic patients showed no difference in ghre-
lin serum concentrations in both groups (Figure 1b),
possibly indicating that critical illness by itself and not
inflammation or endotoxemia is the primarily driving
ghrelin elevation.
Ghrelin serum concentrations in critically ill patients are 
not associated with underlying etiologies
We could previously demonstrate in patients with liver
cirrhosis that ghrelin serum concentrations are not corre-
lated with liver function, but are increased in advanced
stages (for example, Child C cirrhosis) and in case of
complications of chronic liver disease [23]. To test the
impact of the underlying etiology of critical illness we
performed extensive subgroup analysis. Therefore, non-
sepsis patients were divided into liver cirrhosis and others
(mostly cardiovascular disorders) and sepsis patients into
pulmonary and abdominal site of infection (Figure 1c).
We especially focused on the cohort of patients with
abdominal sepsis to account for a suggested link to ghre-
lin levels, as it has been recently reported that ghrelin
administration ameliorates sepsis-induced derange-
m e n t s  o f  g u t  b a r r i e r  f u n c t i o n  i n  a n i m a l  m o d e l s  [ 1 3 ] .
However, although we could demonstrate a trend to
higher ghrelin serum concentrations in patients with liver
cirrhosis, our findings did not reach statistical signifi-
cance for the different etiological subgroups of pulmo-
nary sepsis,  abdominal sepsis,  liver cirrhosis and  non
sepsis patients as displayed in Figure 1c.
Ghrelin serum concentrations are not correlated with pre-
existing diabetes mellitus or body mass index
Stimulation of appetite and regulation of energy homeo-
stasis have been identified as major functions of ghrelin.
By these means ghrelin directly contributes to obesity
[24]. It is therefore important to exclude that endogenous
ghrelin serum levels found in ICU patients upon admis-
sion solely reflect their nutritional status. We therefore
performed subgroup analyses to evaluate the effect of
pre-existing diabetes mellitus and body mass index (BMI)
on serum ghrelin levels, by comparing diabetic with non-
diabetic as well as patients with BMI <18, BMI 18 to 25,
BMI 25 to 30 and BMI >30 kg/m². No significant correla-
tion between pre-existing diabetes mellitus or short
weight, normal weight, overweight and obesity could be
demonstrated (Figure 2a, b and data not shown).
Ghrelin serum concentrations are not correlated to markers 
of inflammation or hepatic function in critically ill patients
In contrast to our findings (Figure 1), decreased levels of
ghrelin in some rodent models of polymicrobial sepsis
have been demonstrated [21,25]. Additionally, treatment
with ghrelin in these sepsis models reduced serum con-
centrations of proinflammatory cytokines like TNF-α and
IL-6 [12]. In our study we could not reproduce this possi-
ble link of inflammatory markers to ghrelin in the large
cohort of critically ill patients. Indeed, TNF-α, IL-6, white
cell blood count, C-reactive protein or procalcitonin did
not correlate with serum ghrelin concentrations neither
in all ICU-patients, nor in the subgroups of sepsis and
non-sepsis patients in the clinical setting at admission to
the Medical ICU (data not shown). With respect to organ
function, we could not demonstrate a significant correla-
tion between ghrelin and hepatic function as displayed by
concentrations of serum protein, albumin, prothrombin
time, antithrombin III and pseudocholinesterase activity
(data not shown). Of note, ghrelin did not correlate with
growth hormone or insulin-like growth factor-1 (IGF-1)
serum levels either (data not shown).
Ghrelin correlates inversely with renal function and 
markers of glucose metabolism in non-sepsis patients
In total cohort of critically ill patients and the subgroup
of septic patients no significant correlation between ghre-
lin serum concentrations and renal function (for example,
Table 2: Disease etiology of the study population
sepsis non-sepsis
n = 122 n = 48
Etiology of sepsis critical illness
Site of infection n (%)
Pulmonary 72 (59%)
Abdominal 22 (18%)
Other 28 (23%)
Etiology of non-sepsis critical 
illness
n (%)
Decompensated liver cirrhosis 17 (35%)
Cardiopulmonary diseases 18 (38%)
Other 13 (27%)Koch et al. Critical Care 2010, 14:R94
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glomerular filtration rate, cystatin C, creatinine) could be
detected (data not shown). Surprisingly, ghrelin was
inversely associated with renal function in the subgroup
of non-sepsis patients as evidenced by significant correla-
tions with the glomerular filtration rate of cystatin C (r =
-0.415, P = 0.018; Figure 3a), indicating that reduced renal
clearance might contribute to increased serum ghrelin in
these patients. This suggests different regulatory mecha-
nisms of ghrelin in critical illness either due to septic or
non-septic etiologies. This hypothesis is further sup-
ported by our finding of a close inverse correlation of
ghrelin with serum glucose (r = -0.369, P = 0.018) and
insulin (r = -0.406, P = 0.019) as important markers of
carbohydrate metabolism in non-sepsis patients at
admission to the ICU (Figure 3b, c), but not in sepsis
patients.
High ghrelin levels indicate a favourable prognosis in 
sepsis patients
To assess the impact of ghrelin on ICU- and overall-sur-
vival during a nearly three-year follow-up period among
all critically ill patients and the subgroups of sepsis and
Figure 1 Serum ghrelin concentrations in critically ill patients. (A) Serum ghrelin levels are significantly (P <0.001, U-test) elevated in critically ill 
patients (n = 170) as compared to healthy controls (n = 60). (B) No significant differences are detected between ICU patients with sepsis and non-
septic etiology of critical illness. (C) Ghrelin serum concentrations are not associated with underlying disease etiology. Box plot are displayed, where 
the bold line indicates the median per group, the box represents 50% of the values, and horizontal lines show minimum and maximum values of the 
calculated non-outlier values; asterisks and open circles indicate outlier values.
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non-sepsis patients we performed Cox regression analy-
ses and used Kaplan-Meier curves. For the total cohort of
all critical care patients, we could not demonstrate an
association between survival and ghrelin serum levels
using uni- and multivariate Cox regression analysis (data
not shown). Likewise, ghrelin serum concentrations did
not correlate with survival in non-sepsis patients (data
not shown). Remarkably, high ghrelin serum concentra-
tions upon admission to the Medical ICU were a predic-
tor for a favourable prognosis concerning ICU-mortality
in sepsis patients (P = 0.0324). Using a cut-off value for
serum ghrelin of 20 pmol/L, Kaplan-Meier curves dis-
played significantly improved survival on the ICU for
sepsis patients with high ghrelin (log rank 4.58). In line,
surviving sepsis patients had significantly higher ghrelin
serum concentrations (median 19.1 pmol/L) than non-
survivors (median 16.3 pmol/L, P = 0.016, U-Test; Figure
4a).
Ghrelin is significantly associated with the necessity of 
ventilation in critically ill patients
A protective effect of ghrelin on severe sepsis induced
acute lung injury (ALI), mediated by inhibition of NF-κB-
pathway in the lungs, has been demonstrated in animal
models [14]. In order to possibly translate this protective
effect of ghrelin on pulmonary function into critically ill
patients in a medical ICU, ghrelin was correlated to the
necessity of ventilation as an indirect marker of pulmo-
nary function. Ghrelin serum concentrations at admis-
sion to ICU were significantly higher if no mechanical
ventilation was required in the total cohort of all critically
ill patients (P = 0.026) and in sepsis patients as well (P =
0.022; Figure 4b).
Discussion
Contradictory findings on the responses of ghrelin to
endotoxin in animal models have been reported, and data
are not fully consistent [21,22]. Current data either dem-
onstrated increased or decreased ghrelin concentrations
after administration of endotoxin. In a rat model of cecal
ligation and puncture (CLP) induced sepsis, significantly
decreased ghrelin serum concentrations at early (5 h after
CLP) and late (20 h after CLP) stages of sepsis were
reported. In contrast, elevated ghrelin serum concentra-
tions and a strong association of ghrelin to markers of
inflammation and hepatic and renal function were
observed in dogs after endotoxinaemia [22]. As a conclu-
sion of this study, elevated ghrelin levels have been con-
sidered as an “adaptive protective response to endotoxin”.
These findings are supported by a previous study in rats
where serum ghrelin levels were found to be significantly
increased upon endotoxin shock [26]. Furthermore, this
study demonstrated a therapeutic effect of ghrelin infu-
sion by the means of a significantly decreased mortality
rate and ameliorated hypotension due to septic shock.
Little is known about the function of ghrelin in sepsis in
humans. A study on healthy volunteers identified ghrelin
as one of the first hormones increasing in the physiologi-
Figure 2 Association of serum ghrelin with diabetes mellitus and body mass index in critically ill patients. (A) Serum ghrelin levels do not dif-
fer between patients with (n = 56) or without (n = 114) pre-existing diabetes mellitus on admittance to the ICU. (B) In subgroup analysis of patients 
with BMI <18 (n = 5), BMI 18 to 25 (n = 63), BMI 25 to 30 (n = 43) and BMI >30 kg/m2 (n = 40) no differences in serum ghrelin concentrations can be 
demonstrated. Box plot are displayed, where the bold line indicates the median per group, the box represents 50% of the values, and horizontal lines 
show minimum and maximum values of the calculated non-outlier values; asterisks and open circles indicate outlier values.
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cal response to endotoxinaemia [17]. There are no data
on the profiles of circulating ghrelin levels in critically ill
patients treated at a medical ICU. In a small study of 25
surgical patients with postoperative intraabdominal sep-
sis elevated ghrelin levels have been reported [27]. In
contrast, a study of 16 surgical and non-surgical ICU
patients showed significantly reduced serum ghrelin lev-
els [18]. Before promoting ghrelin as a new therapeutic
target in intensive care medicine it is (in our opinion)
essential to elucidate the regulation of ghrelin in human
critical illness, sepsis and septic shock from a clinical
point of view. In the present study we can demonstrate
for the first time in a large, well characterized cohort of
patients from a medical ICU that ghrelin levels are signif-
icantly elevated in all critically ill patients as compared to
healthy controls, albeit with a considerable overlap
between both groups (Figure 1a). Ghrelin serum concen-
trations did not differ between sepsis and non-sepsis
patients, which might indicate that high serum ghrelin
levels rather reflect the impact of critical disease than
Figure 3 Impact of organ dysfunction and markers of metabolism on serum ghrelin in non-sepsis patients. (A) Serum ghrelin concentrations 
are elevated in non-sepsis ICU patients with renal failure, as demonstrated by a correlation with serum creatinine and an inverse correlation with the 
glomerular filtration rate (GFR, calculated using serum cystatin C measurements). (B, C) Markers of carbohydrate metabolism, such as glucose and 
insulin, are inversely correlated with serum ghrelin concentrations in non-sepsis ICU patients. Spearman rank correlation test, correlation coefficient r 
and P-values are given.
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being directly influenced by inflammatory cytokines in
sepsis or septic shock (Figure 1b). According to this we
could not demonstrate any correlation of ghrelin with
classical  markers of inflammation as white blood cell
count, C-reactive protein, procalcitonin, TNF-α or IL-6.
Ghrelin stimulates physiologically growth hormone
(GH) secretion independent of hypothalamic GH-releas-
ing hormone and causes weight gain and obesity by
increasing food intake and diminishing lipid utilisation in
non-critically ill individuals [28,29]. Before a meal ghrelin
serum levels rise and show an abrupt decline at the begin-
ning of food intake with trough levels within one hour
after eating [30]. Ghrelin serum levels are decreased in
obese patients and elevated in patients with anorexia ner-
vosa [31,32]. In our study population of critically ill
patients we could not establish a significant correlation
between ghrelin and the body mass index as a parameter
reflecting the nutritional status upon admission to ICU.
This observation strongly indicates that ghrelin regula-
tion is not primarily driven by the current nutritional sta-
tus, but by mechanisms related to the stress of critical
disease.
In fact, the mechanisms of ghrelin release are not satis-
fyingly understood at present. The most important factor
is food intake, but possibly blood glucose and insulin may
participate in regulation [24]. However, we found a close
inverse correlation of ghrelin with serum glucose and
insulin only in the subgroup of non-sepsis patients (Fig-
ure 3b, c), but not in sepsis patients. It is therefore very
likely that additional, so far not apparent factors in the
complex and multifactorial metabolic disturbance in crit-
ically ill patients impact serum ghrelin. Similarly, the
growth hormone and IGF-1 axis, both targets of physio-
logical ghrelin effects, have been reported to be heavily
deranged in ICU patients [33]. However, direct therapeu-
tic intervention by administration of growth hormone in
critically ill patients resulted in increased mortality [34].
This underlines that the changes of metabolism in critical
illness and sepsis are complex, multifactorial, and future
studies are warranted to unravel these interactions.
Furthermore, we could identify high ghrelin levels as a
prognostic marker for survival at the ICU in sepsis
patients (Figure 4). Assuming that high ghrelin levels
have protective effects in sepsis, as demonstrated by
ghrelin administration in several animal studies [11,13-
15], our findings support the concept to view ghrelin
upregulation as beneficial in severe sepsis and septic
shock in humans. Several mechanisms may concertedly
mediate the benefical effect of circulating ghrelin. Specif-
ically, intravenous Ghrelin administration in healthy
humans or animal studies has been found to reduce
peripheral vascular resistance and increase cardiac out-
put without a significant change in heart rate, resulting in
improved tissue perfusion [11,35]. Ghrelin also exerted
protective effects in an experimental model of acute,
endotoxin-induced kidney failure [15]. Furthermore,
Figure 4 Prognostic relevance of serum ghrelin in critically ill patients. (A) Kaplan-Meier survival curves of ICU patients with sepsis (n = 122) are 
displayed, showing that sepsis patients with high ghrelin levels (>20 pmol/L, black) have a decreased short-term mortality at the ICU as compared to 
patients with low ghrelin (≤20 pmol/L, grey). P-value from Cox regression analysis is given. (B) For the total cohort of all critically ill patients (sepsis and 
non-sepsis), ghrelin serum concentrations at admission to the ICU were significantly higher if no mechanical ventilation was required (P = 0.026). Box 
plot are displayed, where the bold line indicates the median per group, the box represents 50% of the values, and horizontal lines show minimum 
and maximum values of the calculated non-outlier values; asterixes and open circles indicate outlier values.
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ghrelin mediated protective effects on pulmonary func-
tion though inhibition of NF-κB in an animal model of
acute lung injury [14]. Regarding the necessity of
mechanical ventilation as a surrogate parameter of pul-
monary function in patients, we could demonstrate sig-
nificantly higher ghrelin serum concentrations in
spontaneous breathing critically ill patients as compared
with mechanically ventilated patients (Figure 4b). That
might advert to pulmonary protective effects of high
ghrelin serum concentrations in critically ill patients,
keeping in mind that ghrelin regulation is most likely
multifactorial and not fully understood.
Conclusions
We could demonstrate, for the first time, high ghrelin lev-
els in critically ill patients as compared to healthy con-
trols, independent of the presence of sepsis or
inflammatory markers. Moreover, high ghrelin levels
were a positive predictor of ICU-survival in sepsis
patients, matching previous results from animal models.
Nevertheless, the regulation of cytokines, adipokines and
hormones with metabolic functions in critical illness is
complex, and both, future experimental and clinical stud-
ies are needed to identify and evaluate ghrelin as a poten-
tial new therapeutic agent in critical care medicine.
Key messages
• Recent animal studies identified ghrelin, a stomach-
derived ligand for the growth hormone receptor, as a
mediator of various beneficial effects in sepsis.
• Ghrelin serum concentrations are significantly ele-
vated in critically ill patients at admission to the ICU,
but do not differ between sepsis and non-sepsis
patients.
• High ghrelin levels indicate a favourable prognosis
in sepsis patients.
• Low ghrelin is associated with the necessity of venti-
lation as a parameter of adverse pulmonary function
in ICU patients, and serum ghrelin correlates with
renal function in non-sepsis patients.
• Our data support the further investigation of ghrelin
as a prognostic tool in ICU patients and its potential
therapeutic application in sepsis.
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